TTNP: Titan Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TTNP: Titan Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 6.59
Enterprise Value ($M) 0.33
Book Value ($M) 6.64
Book Value / Share 7.27
Price / Book 0.99
NCAV ($M) 6.57
NCAV / Share 7.19
Price / NCAV 1.00

Profitability (mra)
Return on Invested Capital (ROIC) -0.77
Return on Assets (ROA) -2.57
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 5.55
Current Ratio 5.55

Balance Sheet (mrq) ($M)
Current Assets 8.02
Assets 8.09
Liabilities 1.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.18
Operating Income -7.28
Net Income -5.57
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -7.09
Cash from Investing 0.73
Cash from Financing 10.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-05 13D/A Sire Group Ltd. 14.10 -95.00
07-21 13D Choong Choon Hau 24.95
06-23 13D/A Activist Investing LLC 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. ☐ TRANSITION REPORT PURSUAN
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. ☐ TRANSITION REPORT PURSUANT TO
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 126 2,429 5.19
2024-04-23 37 344 10.76
2024-04-22 52 324 16.05
2024-04-19 510 30 1,700.00

(click for more detail)

Similar Companies
TPST – Tempest Therapeutics, Inc. TRAW – Traws Pharma, Inc.
TRVN – Trevena, Inc. UNCY – Unicycive Therapeutics, Inc.
UPC – Universe Pharmaceuticals INC


Financial data and stock pages provided by
Fintel.io

Finpedia: Titan Pharmaceuticals